ESMO21

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced results from the Phase 1b/2 NORSE study evaluating Balversa (erdafitinib) plus cetrelimab combination. The trial included patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast...

TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.  The data will be at the European Society for Medical Oncology (ESMO21) Congress 2021. Gavo-...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced four e-poster presentations at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.  The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib plus paclitaxel in...

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology (ESMO21) Congress 2021. The trial included 178 patients with recurrent platinum-resistant...

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021. The trial included patients with unresectable,...

Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterologous prime-boost in combination with Bristol-Myers Squibb Co's (NYSE: BMY...

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial. Related: Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial. The trial is evaluating...

Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 (ESMO21) presented the therapy's effect on the quality of life and pain...

Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021. Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer. The Phase 2 trial...

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations.  The data was presented at the 2021 ESMO...

NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced preliminary findings from its ongoing Phase 1a/1b dose-escalation study of NGM120 in solid tumors. Related Link: Raymond James Upgraded This Biopharma Stock And Sees 44% Upside. The data were presented at the European Society...

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology (ESMO21) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers...

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society for Medical Oncology (ESMO21) Virtual Conference. Data: 39 metastatic...

Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Data were presented at the European Society for Medical Oncology Virtual...

Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies. The results were presented at the...